JP2009502937A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502937A5 JP2009502937A5 JP2008524094A JP2008524094A JP2009502937A5 JP 2009502937 A5 JP2009502937 A5 JP 2009502937A5 JP 2008524094 A JP2008524094 A JP 2008524094A JP 2008524094 A JP2008524094 A JP 2008524094A JP 2009502937 A5 JP2009502937 A5 JP 2009502937A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- kinase
- abl kinase
- mutant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 7
- 102000030951 Phosphotransferases Human genes 0.000 claims 3
- 108091000081 Phosphotransferases Proteins 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 206010008943 Chronic leukaemia Diseases 0.000 claims 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims 1
- 230000035943 smell Effects 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (10)
- 化合物ＩとＡｂｌキナーゼとを接触させることを包含する、該Ａｂｌキナーゼを阻害する方法。
- 前記Ａｂｌキナーゼが野生型キナーゼである、請求項１に記載の方法。
- 前記Ａｂｌキナーゼが、該Ａｂｌキナーゼの変異型である、請求項１に記載の方法。
- 前記Ａｂｌキナーゼの変異型がＴ３１５Ｉ変異体である、請求項３に記載の方法。
- 化合物Ｉまたは該化合物Ｉの薬学的に許容できる塩を含む、患者においてＣＭＬを処置するための組成物。
- 化合物Ｉまたは該化合物Ｉの薬学的に許容できる塩を含む、患者においてＡＬＬを処置するための組成物。
- Ａｂｌキナーゼの阻害を必要とする患者において該Ａｂｌキナーゼを阻害するための組成物であって、
化合物Ｉ
を含む、組成物。 - 前記Ａｂｌキナーゼが変異体Ａｂｌキナーゼである、請求項７に記載の組成物。
- 前記変異体ＡｂｌキナーゼがＴ３１５Ｉ変異体である、請求項８に記載の組成物。
- 化合物Ｉを含む治療組成物であって、該組成物は、Ｔ３１５Ｉ Ａｂｌ変異が存在する患者に投与されることを特徴とする、組成物。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70277105P | 2005-07-26 | 2005-07-26 | |
| US78516106P | 2006-03-23 | 2006-03-23 | |
| US83025706P | 2006-07-12 | 2006-07-12 | |
| PCT/US2006/028984 WO2007014250A2 (en) | 2005-07-26 | 2006-07-26 | Abl kinase inhibition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012122081A Division JP2012158616A (ja) | 2005-07-26 | 2012-05-29 | Ａｂｌキナーゼ阻害 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009502937A JP2009502937A (ja) | 2009-01-29 |
| JP2009502937A5 true JP2009502937A5 (ja) | 2009-09-10 |
Family
ID=37683933
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008524094A Pending JP2009502937A (ja) | 2005-07-26 | 2006-07-26 | Ａｂｌキナーゼ阻害 |
| JP2012122081A Pending JP2012158616A (ja) | 2005-07-26 | 2012-05-29 | Ａｂｌキナーゼ阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012122081A Pending JP2012158616A (ja) | 2005-07-26 | 2012-05-29 | Ａｂｌキナーゼ阻害 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090298844A1 (ja) |
| EP (1) | EP1906967A4 (ja) |
| JP (2) | JP2009502937A (ja) |
| AU (1) | AU2006272609A1 (ja) |
| CA (1) | CA2616517A1 (ja) |
| WO (1) | WO2007014250A2 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1960546B1 (en) * | 2005-12-01 | 2011-10-19 | Bristol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting complex karyotypes |
| EP2051737A2 (en) * | 2006-07-26 | 2009-04-29 | Merck & Co., Inc. | A novel lactic acid formulation of mk-0457 useful for the treatment of cancer |
| NZ700928A (en) | 2012-04-24 | 2017-06-30 | Vertex Pharma | Dna-pk inhibitors |
| LT3527563T (lt) | 2013-03-12 | 2021-12-10 | Vertex Pharmaceuticals Incorporated | Dnr-pk inhibitoriai |
| CA2907243C (en) | 2013-03-15 | 2021-12-28 | Celgene Avilomics Research, Inc. | Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor |
| MX2015011514A (es) | 2013-03-15 | 2016-08-11 | Celgene Avilomics Res Inc | Compuestos de heteroarilo y sus usos. |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| PT3424920T (pt) | 2013-10-17 | 2020-07-07 | Vertex Pharma | Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk |
| KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2290056A3 (en) * | 2001-10-05 | 2011-06-01 | Novartis AG | Mutated Abl kinase domains |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| KR20070049655A (ko) * | 2004-08-13 | 2007-05-11 | 제넨테크, 인크. | Ａｔｐ-이용 효소 억제 활성을 나타내는2-아미도-티아졸-기재 화합물과 조성물 및 이들의 용도 |
-
2006
- 2006-07-26 AU AU2006272609A patent/AU2006272609A1/en not_active Abandoned
- 2006-07-26 CA CA002616517A patent/CA2616517A1/en not_active Abandoned
- 2006-07-26 US US11/989,300 patent/US20090298844A1/en not_active Abandoned
- 2006-07-26 WO PCT/US2006/028984 patent/WO2007014250A2/en active Application Filing
- 2006-07-26 EP EP06800350A patent/EP1906967A4/en not_active Withdrawn
- 2006-07-26 JP JP2008524094A patent/JP2009502937A/ja active Pending
-
2012
- 2012-05-29 JP JP2012122081A patent/JP2012158616A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009502937A5 (ja) | ||
| CA2869269C (en) | Use of ccr3-inhibitors | |
| BRPI0506765A (pt) | composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição | |
| JP2013507415A5 (ja) | ||
| JP2005506370A5 (ja) | ||
| NO20081843L (no) | Farmasoytisk sammensetning for forbedret kognitiv funksjon | |
| EA201000365A1 (ru) | Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза | |
| JP2008502696A5 (ja) | ||
| EA201692214A1 (ru) | Вещества, связывающие ядерные рецепторы | |
| ITBO20110012A1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| JP2009541443A5 (ja) | ||
| JP2012508734A5 (ja) | ||
| JP2019511489A5 (ja) | ||
| JP2018090566A5 (ja) | ||
| NO20065152L (no) | Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav | |
| JP2013507442A5 (ja) | ||
| BRPI0607003A2 (pt) | forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda | |
| TN2009000452A1 (en) | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof | |
| JP2009062388A5 (ja) | ||
| JP2008533021A5 (ja) | ||
| JP2008513426A5 (ja) | ||
| JP2009541409A5 (ja) | ||
| TW200732304A (en) | Piperidine derivatives | |
| CA2595363A1 (en) | Methods and materials with trans-clomiphene for the treatment of male infertility | |
| TNSN08506A1 (en) | Substituted carboxamides |